EE692 Cost-Effectiveness of Nivolumab (NIVO) and NIVO in Combination With Ipilimumab (IPI) in First-Line Treatment of Advanced Melanoma in Colombia: Analysis Using 78-Month Overall Survival From CheckMate 067
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.957
https://www.valueinhealthjournal.com/article/S1098-3015(23)04087-1/fulltext
Title :
EE692 Cost-Effectiveness of Nivolumab (NIVO) and NIVO in Combination With Ipilimumab (IPI) in First-Line Treatment of Advanced Melanoma in Colombia: Analysis Using 78-Month Overall Survival From CheckMate 067
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04087-1&doi=10.1016/j.jval.2023.09.957
First page :
Section Title :
Open access? :
No
Section Order :
10447